Den Europæiske Union - dansk - EMA (European Medicines Agency)

lipomed gmbh - thalidomid - multipelt myelom - immunosuppressiva - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

lipomed gmbh - deferiprone - iron overload; beta-thalassemia - alle andre terapeutiske produkter - deferiprone lipomed monoterapi er indiceret til behandling af jernophobning i patienter med thalassaemia major, når de nuværende kelation terapi er kontraindiceret eller utilstrækkelige. deferiprone lipomed i kombination med en anden chelator er indiceret hos patienter med thalassaemia major, når monoterapi med nogen strygejern chelator er ineffektive, eller når forebyggelse og behandling af livstruende konsekvenser af jernophobning begrunder hurtige eller intensiv korrektion.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - ciprofloxacinhydrochlorid, vandfrit - filmovertrukne tabletter - 250 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orion corporation - ciprofloxacinhydrochlorid (monohydrat) - filmovertrukne tabletter - 250 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka sverige ab - ciprofloxacinhydrochlorid (monohydrat) - filmovertrukne tabletter - 250 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - ciprofloxacinhydrochlorid, vandfrit - filmovertrukne tabletter - 250 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

navamedic asa - ciprofloxacin - infusionsvæske, opløsning - 2 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

hexal a/s - ciprofloxacin - filmovertrukne tabletter - 250 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - ciprofloxacin - infusionsvæske, opløsning - 2 mg/ml